N. Azli

2.2k total citations
35 papers, 1.7k citations indexed

About

N. Azli is a scholar working on Oncology, Otorhinolaryngology and Dermatology. According to data from OpenAlex, N. Azli has authored 35 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 11 papers in Otorhinolaryngology and 11 papers in Dermatology. Recurrent topics in N. Azli's work include Cancer Treatment and Pharmacology (18 papers), Head and Neck Cancer Studies (11 papers) and Chemotherapy-related skin toxicity (10 papers). N. Azli is often cited by papers focused on Cancer Treatment and Pharmacology (18 papers), Head and Neck Cancer Studies (11 papers) and Chemotherapy-related skin toxicity (10 papers). N. Azli collaborates with scholars based in France, Belgium and Spain. N. Azli's co-authors include Esteban Cvitkovic, A. Riva, Véronique Dièras, M. Bachouchi, P. Fumoleau, Jean‐Pierre Armand, P. Wibault, P Pouillart, B Chevallier and Pierre Kerbrat and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

N. Azli

35 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
N. Azli France	19	1.4k	494	465	323	321	35	1.7k
Glenn Cummings United States	18	838 0.6×	129 0.3×	599 1.3×	36 0.1×	694 2.2×	30	1.8k
Naveen Faridi Pakistan	24	570 0.4×	345 0.7×	110 0.2×	79 0.2×	291 0.9×	85	1.4k
Juan J. Grau Spain	21	847 0.6×	81 0.2×	688 1.5×	54 0.2×	438 1.4×	60	1.7k
Jay Wasman United States	20	446 0.3×	161 0.3×	138 0.3×	35 0.1×	295 0.9×	63	1.3k
Paweł Golusiński Poland	23	349 0.3×	401 0.8×	400 0.9×	83 0.3×	348 1.1×	87	1.3k
Asawari Patil India	16	380 0.3×	151 0.3×	212 0.5×	56 0.2×	284 0.9×	88	927
Halvor Vermund United States	20	547 0.4×	124 0.3×	549 1.2×	73 0.2×	453 1.4×	70	1.3k
Khai Mun Lee Singapore	16	607 0.4×	105 0.2×	726 1.6×	63 0.2×	604 1.9×	26	1.4k
József Erfán Hungary	5	1.5k 1.1×	256 0.5×	1.4k 3.0×	38 0.1×	769 2.4×	6	2.6k
Andrzej Kawecki Poland	11	1.8k 1.3×	295 0.6×	1.6k 3.5×	43 0.1×	923 2.9×	46	3.1k

Countries citing papers authored by N. Azli

Since Specialization

Citations

This map shows the geographic impact of N. Azli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. Azli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. Azli more than expected).

Fields of papers citing papers by N. Azli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N. Azli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. Azli. The network helps show where N. Azli may publish in the future.

Co-authorship network of co-authors of N. Azli

This figure shows the co-authorship network connecting the top 25 collaborators of N. Azli. A scholar is included among the top collaborators of N. Azli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N. Azli. N. Azli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cresta, Sara, Giacomo Grasselli, Mauro Mansutti, et al.. (2004). A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer. Annals of Oncology. 15(3). 433–439. 29 indexed citations

Paridaens, Robert, F. Van Aelst, Vassilis Georgoulias, et al.. (2003). A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer. Annals of Oncology. 14(3). 433–440. 18 indexed citations

Vasey, P., Henri Roché, D. Bisset, et al.. (2002). Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer. British Journal of Cancer. 87(10). 1072–1078. 3 indexed citations

Campone, Mario, P. Fumoleau, Valérie Delecroix, et al.. (2001). Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer. Annals of Oncology. 12(7). 909–918. 20 indexed citations

Taamma, A., A. Fandi, N. Azli, et al.. (1999). Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type. Cancer. 86(7). 1101–1108. 47 indexed citations

Misset, J. L., Véronique Dièras, G. Gruia, et al.. (1999). Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer. Annals of Oncology. 10(5). 553–560. 106 indexed citations

Bruno, René, Nicole Vivier, Guy Montay, et al.. (1999). The cycle-to-cycle variability of docetaxel pharmacokinetics (PK) assessed by population PK analysis. European Journal of Cancer. 35. S194–S194. 3 indexed citations

Fandi, Abderrahim, A. Taamma, N. Azli, et al.. (1997). Palliative treatment with low-dose continuous infusion 5-fluorouracil in recurrent and/or metastatic undifferentiated nasopharyngeal carcinoma type. Head & Neck. 19(1). 41–47. 15 indexed citations

Dièras, Véronique, et al.. (1997). Docetaxel in combination with doxorubicin or vinorelbine. European Journal of Cancer. 33. S20–S22. 21 indexed citations

10.

Dièras, Véronique, B Chevallier, Pierre Kerbrat, et al.. (1996). A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. British Journal of Cancer. 74(4). 650–656. 74 indexed citations

11.

Fumoleau, P., B Chevallier, Pierre Kerbrat, et al.. (1996). A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the Clinical Screening Group of the EORTC. Annals of Oncology. 7(2). 165–171. 88 indexed citations

12.

Chevallier, B, P. Fumoleau, Pierre Kerbrat, et al.. (1995). Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.. Journal of Clinical Oncology. 13(2). 314–322. 184 indexed citations

13.

Rousselet, Germain, M. Bachouchi, Pierre Busson, et al.. (1993). Clinical implications of the serum level of CD23 in patients with undifferentiated nasopharyngeal carcinoma.. Journal of Clinical Oncology. 11(11). 2143–2149. 9 indexed citations

14.

Cvitkovic, Esteban, M. Bachouchi, Hamouda Boussen, et al.. (1993). Leukemoid reaction, bone marrow invasion, fever of unknown origin, and metastatic pattern in the natural history of advanced undifferentiated carcinoma of nasopharyngeal type: a review of 255 consecutive cases.. Journal of Clinical Oncology. 11(12). 2434–2442. 65 indexed citations

15.

Bachouchi, M., Jean‐Nicolas Munck, Pierre Busson, et al.. (1993). Phase II trial of recombinant interferon gamma in refractory undifferentiated carcinoma of the nasopharynx. Head & Neck. 15(2). 115–118. 10 indexed citations

16.

Recondo, Gonzálo, Esteban Cvitkovic, N. Azli, et al.. (1991). Neoadjuvant chemotherapy consisting of cisplatin and continuous infusions of bleomycin and 5-fluorouracil for advanced head and neck cancer. The need for a new stratification for stage IV (MO) disease. Cancer. 68(10). 2109–2119. 16 indexed citations

17.

Boussen, Hamouda, Esteban Cvitkovic, J. L. Wendling, et al.. (1991). Chemotherapy of metastatic and/or recurrent undifferentiated nasopharyngeal carcinoma with cisplatin, bleomycin, and fluorouracil.. Journal of Clinical Oncology. 9(9). 1675–1681. 108 indexed citations

18.

Bachouchi, M., Esteban Cvitkovic, N. Azli, et al.. (1990). High Complete Response in Advanced Nasopharyngeal Carcinoma With Bleomycin, Epirubicin, and Cisplatin Before Radiotherapy. JNCI Journal of the National Cancer Institute. 82(7). 616–620. 93 indexed citations

19.

Bachouchi, M., Esteban Cvitkovic, Hamouda Boussen, et al.. (1990). Nasopharyngeal carcinoma: A medical oncology viewpoint. The Gustave Roussy experience. Annals of Oncology. 1(4). 245–253. 18 indexed citations

20.

Klijanienko, Jerzy, C Micheau, N. Azli, et al.. (1989). Undifferentiated Carcinoma of Nasopharyngeal Type of Tonsil. Archives of Otolaryngology - Head and Neck Surgery. 115(6). 731–734. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact